Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | mitogen-activated protein kinase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 1 | 360 aa | 361 aa | 33.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.052 | 0.5905 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0062 | 0 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0062 | 0 | 0.5 |
Plasmodium falciparum | dipeptidyl aminopeptidase 2 | 0.0838 | 1 | 1 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0062 | 0 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0062 | 0 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0062 | 0 | 0.5 |
Schistosoma mansoni | dipeptidyl-peptidase I (C01 family) | 0.0838 | 1 | 1 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0062 | 0 | 0.5 |
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | 0.0838 | 1 | 1 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0062 | 0 | 0.5 |
Toxoplasma gondii | cathepsin CPC2 | 0.0318 | 0.3302 | 0.3302 |
Giardia lamblia | Encystation-specific protease | 0.0318 | 0.3302 | 0.3302 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0318 | 0.3302 | 0.3302 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0062 | 0 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0062 | 0 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0062 | 0 | 0.5 |
Toxoplasma gondii | preprocathepsin c precursor, putative | 0.0838 | 1 | 1 |
Brugia malayi | MAP kinase sur-1 | 0.0062 | 0 | 0.5 |
Toxoplasma gondii | cathepsin CPC1 | 0.0838 | 1 | 1 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0318 | 0.3302 | 0.3302 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0062 | 0 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0062 | 0 | 0.5 |
Plasmodium vivax | dipeptidyl aminopeptidase 1, putative | 0.0838 | 1 | 1 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0062 | 0 | 0.5 |
Plasmodium vivax | dipeptidyl aminopeptidase 2, putative | 0.0838 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.7803 nM | BindingDB_Patents: IMAP-FP Assay. Activated ERK2 activity was determined in an IMAP-FP assay (Molecular Devices). Using this assay format, the potency (IC50) of each compound was determined from a 10 point (1:3 serial dilution, 3 uM starting compound concentration) titration curve using the following outlined procedure. To each well of a black Corning 384-well plate (Corning Catalog #3575), 7.5 mL of compound (3333 fold dilution in final assay volume of 25 uL) was dispensed, followed by the addition of 15 uL of kinase buffer (tween containing kinase buffer, Molecular Devices) containing 0.0364 ng/mL (0.833 nM) of phosphorylated active hERK2 enzyme. Following a 15 minute compound & enzyme incubation, each reaction was initiated by the addition of 10 uL kinase buffer containing 2.45 uM ERK2 IMAP substrate peptides (2.25 uM-unlabeled IPTTPITTTYFFFK-COOH and 200 nM-labeled IPTTPITTTYFFFK-5FAM (5-carboxyfluorescein)-COOH), and 75 uM ATP. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.